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Supplementary Introduction section 1 
The endocannabinoid system 
The endocannabinoid system (ECS) is a complex signalling network comprising 
endogenous ligands (i.e. the “endocannabinoids” [eCB], such as 
arachidonoylethanolamine, also known as anandamide [AEA] or 2-
arachidonoylglycerol [2-AG], etc.), various cannabinoid-sensitive receptors (e.g. 
cannabinoid [CB]-1 and -2, several transient receptor potential [TRP] channels, etc.) 
as well as enzymes and transporters being responsible for the synthesis (e.g. N-acyl 
phosphatidylethanolamine specific phospholipase D, diacylglycerol lipases-α and –β) 
and degradation (fatty acid amide hydrolase [FAAH], monoacylglycerol lipase, 
endocannabinoid membrane transporter [EMT]) of the eCBs (18,19,s1-3). 
 
The ECS was shown to regulate various physiological functions all over the body. In 
the central nervous system (CNS), it regulates behaviour, mood, appetite, and 
memory in a chiefly CB1-dependent manner, whereas its best-characterized activities 
at the periphery are coupled to the regulation of the immune system via the activation 
of CB2 (18,19,s1-3). Therefore, although both receptors can be found in both 
locations, CB2 is very often referred to be the “anti-inflammatory, peripheral”, 
whereas CB1 the “psychotropic, central” cannabinoid receptor. 
 
Besides, ECS has also been proven to be functionally active in the (human) skin. 
Indeed, in a wider context, cutaneous ECS is an important part of the complex 
neuroendocrine system of the skin (extensively reviewed by Slominski et al.; 16,17), 
controlling several fundamental cutaneous functions, such as e.g. hair growth, 
sebaceous lipid production, mast cell maturation and degranulation, fibroblast 
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functions, melanogenesis, keratinocyte proliferation and differentiation, etc. (for 
details, see 19,20,s4-5). 
 
Supplementary Introduction section 2 
Plant-derived or “phyto”-cannabinoids (pCBs) are characteristic molecules of the 
plant Cannabis sativa. Among the cca. 100 different pCBs (-)-trans-Δ9-
tetrahydrocannabinol (THC) is the best studied one, since it is the major responsible 
for the CB1 receptor-coupled psychotropic effects of the Cannabis-derived drugs, i.e. 
marijuana and hashish (19,20,s2). Of great importance, the vast majority of the 
remaining pCBs are non-psychotropic ones due to the lack of CB1 agonism (21,s6-
10). Since one of the greatest challenges of the cannabinoid-based drug 
development is to avoid CB1-coupled psychotropic side-effects (19,20,s1-2), these 
pCBs are exceptional candidates for future drug development. 
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Supplementary Methods 
 
Determination of cellular viability 
The viability of the cells was determined by measuring the conversion of the 
tetrazolium salt MTT (Sigma-Aldrich) to formazan by mitochondrial dehydrogenases. 
Cells were plated in 96-well plates (20,000 cells/well) in quadruplicates, and were 
treated as indicated for 1 or 2 days. Cells were then incubated with 0.5 mg/ml MTT 
for 2 hrs, and concentration of formazan crystals (as an indicator of number of viable 
cells) was determined colorimetrically at 565 nm by using FlexStation 3 multi-mode 
microplate reader (Molecular Devices). Results were expressed as percentage of 
vehicle controls regarded as 100%. 
 
Determination of apoptosis 
A decrease in the mitochondrial membrane potential is one of the earliest markers of 
apoptosis (28,29). Therefore, to assess the process, mitochondrial membrane 
potential of SZ95 sebocytes was determined using a MitoProbe™ DilC1(5) Assay Kit 
(Life Technologies Hungary Ltd.). Cells (20,000 cells/well) were cultured in black 96-
well plates with clear bottom (Greiner Bio One) in quadruplicates and were treated as 
indicated for 24 hrs. After removal of supernatants, cells were incubated for 30 
minutes with DilC1(5) working solution (50 μl/well), then washed with PBS, and the 
fluorescence of DilC1(5) was measured at 630 nm excitation and 670 nm emission 
wavelengths using FlexStation™ II384 fluorometer or FlexStation 3 multi-mode 
microplate reader (Molecular Devices). Relative fluorescence values were expressed 
as percentage of vehicle controls regarded as 100%. As a positive control for 
apoptosis, we applied carbonyl cyanide m-chlorophenyl hydrazone (CCCP; Life 
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Technologies Hungary Ltd.) dissolved in the DilC1(5) working solution (1:200 for 30 
min; Fig. S1). 
 
Determination of necrosis 
Necrotic processes were determined by SYTOX Green staining (Life Technologies 
Hungary Ltd.). The dye is able to penetrate (and then bind to the nucleic acids) only 
to necrotic cells with ruptured plasma membranes, whereas healthy cells with intact 
surface membranes show negligible SYTOX Green staining. Cells were cultured in 
black 96-well plates with clear bottom (Greiner Bio One), and treated as indicated for 
up to 24 hrs. Supernatants were then discarded, and the cells were incubated for 30 
minutes with 1 μM SYTOX Green dye. Following incubation, cells were washed with 
PBS, the culture medium was replaced, and fluorescence of SYTOX Green was 
measured at 490 nm excitation and 520 nm emission wavelengths using 
FlexStation™ II384 fluorometer or FlexStation 3 multi-mode microplate reader 
(Molecular Devices). Relative fluorescence values were expressed as percentage of 
vehicle controls regarded as 100%. As a positive control for necrosis, lysis buffer 
(1:100 in the SYTOX Green working solution for 30 min; Life Technologies Hungary 
Ltd.) was applied (Fig. S1). 
Due to their spectral properties, DilC1(5) and SYTOX Green dyes were always 
administered together, enabling us to investigate necrotic and early apoptotic 
processes of the same cultures. Selective decrease of DilC1(5) intensity indicated 
mitochondrial depolarization (i.e. the onset of early apoptotic processes), whereas 
increase of SYTOX Green staining intensity revealed necrotic cell death. An example 
for typical apoptotic and necrotic alterations are shown in Fig. S1. 
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Supplementary Discussion & Conclusions section 1 
Acne is a multifactorial, inflammation-accompanied skin disease, detrimentally 
affecting quality of life of many patients world-wide (1,4-6). Although nowadays 
several therapeutic tools are available (1,5), we still lack highly efficient, yet safe 
medications; thus many studies intended to reveal such novel possibilities. We have 
previously shown that in human SGs the locally produced AEA and 2-AG promote 
sebaceous lipid synthesis via an auto- and paracrine regulation (20); one promising 
direction could therefore be the appropriate modulation of the ECS (i.e. by 
antagonizing CB2 receptor or reducing the local endocannabinoid concentrations). 
On the other hand, our recently published data describing the potent and complex 
anti-acne effects of CBD in vitro and ex vivo (22) pointed to an entirely new direction, 
i.e. to the administration of certain non-psychotropic pCBs in the management of 
acne, and shed light on previously unknown sebostatic (TRPV4) and anti-
inflammatory (A2A adenosine receptors) therapeutic targets expressed by the 
sebocytes (22). 
THCV (similar to CBD) appears to be a multifaceted, promising, novel anti-acne 
agent efficiently targeting all the three key sebocyte-specific steps of the 
pathogenesis (i.e. increased sebaceous lipid synthesis, proliferation and 
inflammation). Furthermore, it should also be noted that pCBs in general are highly 
likely to have beneficial effects against two major additional, “sebocyte-independent” 
aspects of the acne pathogenesis, i.e. infundibular hyperkeratosis leading to 
comedogenesis and overgrowth of acnegenic bacteria (1,5). Indeed, several pCBs 
were already shown to inhibit differentiation (CBD and CBG) (s11), and to reduce 
proliferation of keratinocytes (e.g. CBD and CBG) (33) making them likely to be 
efficient in suppressing infundibular hyperkeratosis and subsequent comedogenesis, 
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and many of them (e.g. CBD, CBC, CBG, etc.) were evidenced to exert potent anti-
bacterial activity (s12), which augurs to be useful in countering colonization of 
acnegenic Propionibacterium acnes strains. 
 
Supplementary Discussion & Conclusions section 2 
As discussed above, pCBs are well-known to influence the activity of a wide-array of 
cellular targets, including receptors (CB1, CB2, 5-HT1A, adenosine A2A, GPR55, µ 
opioid) enzymes (FAAH, phospholipase A2, cyclooxygenase, lipoxygenase or certain 
cytochrome P450 enzymes, etc.), transporters (EMT, equilibrative nucleotide 
transporter 1, etc.), ion- and non-ion selective pores (certain TRP channels, 5-HT3 
receptor, voltage-dependent anion channel 1, etc.) (21,22,27,36,37,44-46,s3,s6-
11,s13-22). Moreover, in some cases the development of indirect “entourage” effects 
should also be taken into consideration (s11,s14,s23). 
 
According to their varying affinities towards their targets, each pCB can be 
characterized by a more or less unique “fingerprint” of molecular actions, which 
determines the nature of its biological activity. The wide-array of possible interactions 
definitely raises the risk of unwanted and unexpected (!) adverse effects, therefore, 
although the pCBs being currently in use in the clinical practice possess a very 
“desirable” side-effect profile (for details, see Discussion & Conclusions section of 
the main text), introduction of novel (i.e. previously un-tested) pCB-based 
medications in the dermatological practice must be preceded by rigorous pre-clinical 
(e.g. mini-pig studies) and clinical studies to minimize the risk of any harmful actions 
(s24,s25). 
8 
 
 
By administering pCBs, one shall take into consideration at least two major groups of 
side-effects, i.e. psychotropic actions due to the systemic distribution of the 
substances followed by the subsequent activation of the neuronal CB1 expressed in 
the central nervous system, as well as local adverse effects. In our case the first 
option can almost certainly be ruled out due to the non-psychotropic nature of the 
investigated pCBs, which were already shown to lack CB1 agonism in many systems 
(21,s6-10). Moreover, to further minimize the risk of any unexpected actions, specific 
topical formulations are to be developed to help the delivery of the pCBs into the 
skin, but (if possible) to prevent their transcutaneous absorption to the circulation. 
 
On the other hand, we should not forget about the fact that, besides the sebocytes, 
pCBs may reach other cutaneous cells (epidermal keratinocytes, melanocytes, 
Langerhans cells, fibroblasts, cells of the hair follicles, etc.) as well. Although, as 
mentioned in the Discussion & Conclusions section of the main text, due to their 
physicochemical properties, topically administered pCBs are likely to target SGs with 
high selectivity (50) there is a small, but non-negligible chance to influence the 
biology of these cells and cutaneous structures as well. Obviously, these local 
additional (not necessarily adverse!) effects will greatly depend on the 
pharmacokinetic properties (pCB concentration, presence or absence of permeation 
enhancers, etc.) of the given formulations in which the pCB would be administered. 
Thus, upon development of such formulations, the aforementioned, routinely applied 
rigorous pre-clinical and clinical testing must be conducted in the case of the novel, 
pCB-based pharmaceuticals/cosmeceuticals.  
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Supplementary Figures 
 
Supplementary Figure S1 Assessment of the effects of apoptosis and necrosis 
positive controls in human sebocytes 
Cell death of SZ95 sebocytes was investigated by combined fluorescent DilC1(5)-
SYTOX Green labelling. As apoptosis positive control, carbonyl cyanide m-
chlorophenyl hydrazone (CCCP; a well-known un-coupler of the mitochondrial inner 
membrane) was applied (1:200 for 30 min), whereas necrosis was induced by lysis 
buffer (1:100 for 30 min). *** marks significant (P<0.001) differences compared to the 
control group. Note that although CCCP (besides decreasing the mitochondrial 
membrane potential as revealed by DilC1(5) signal intensity) significantly increased 
the SYTOX Green intensity, its action was far exceeded by lysis buffer, which 
induced a dramatic (>2,000%) increase in it. In general, selective >20% decrease of 
DilC1(5) intensity (maybe accompanied by minor, i.e. <50% increase in the SYTOX 
Green staining) indicates the development of “pure” apoptotic processes, whereas 
simultaneous biologically relevant (i.e. >50%) increase of SYTOX Green level marks 
necrotic processes.  
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Supplementary Figure S2 Up to 10 μM, none of the investigated pCBs decreased 
viability of sebocytes following 24- (a) and 48-hr (b) treatments 
Viability of SZ95 sebocytes was monitored by MTT-assay following 24- (a) or 48-hr 
(b) treatments. Results are expressed in the percentage of the vehicle control (100%, 
solid line) as mean±SEM of four independent determinations. Two additional 
experiments yielded similar results. *, ** and *** mark significant (P<0.05, 0.01 or 
0.001, respectively) differences compared to the vehicle control.  
CBC: (-)-cannabichromene; CBDV: (-)-cannabidivarin; CBG: (-)-cannabigerol;  
CBGV: (-)-cannabigerovarin; THCV: (-)-Δ9-tetrahydrocannabivarin.  
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Supplementary Figure S3 High concentrations of the pCBs decreased viability of 
sebocytes 
Viability of SZ95 sebocytes was monitored by MTT-assay following 24-hr treatments. 
Results are expressed in the percentage of the vehicle control (100%, solid line) as 
mean±SEM of four independent determinations. One additional experiment yielded 
similar results. *, ** and *** mark significant (P<0.05, 0.01 or 0.001, respectively) 
differences compared to the vehicle control.  
CBC: (-)-cannabichromene; CBDV: (-)-cannabidivarin; CBG: (-)-cannabigerol;   
CBGV: (-)-cannabigerovarin; THCV: (-)-Δ9-tetrahydrocannabivarin. 
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Supplementary Figure S4 Up to 10 μM, the investigated pCBs induced only minor 
alterations in the ratio of apoptotic or necrotic cells following 24-hr treatments 
(a-e) Apoptotic and necrotic cell death of SZ95 sebocytes was investigated by 
DilC1(5)-SYTOX Green double labelling following the indicated 24-hr treatments. 
Results are expressed in the percentage of the vehicle control (100%, solid line) as 
mean±SEM of four independent determinations. * marks significant (P<0.05) 
differences compared to the vehicle control. One additional experiment yielded 
similar results.   
CBC: (-)-cannabichromene; CBDV: (-)-cannabidivarin; CBG: (-)-cannabigerol;   
CBGV: (-)-cannabigerovarin; THCV: (-)-Δ9-tetrahydrocannabivarin.  
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Supplementary Figure S5 High concentrations of the pCBs induced apoptosis-
dominated cell death 
Apoptotic and necrotic cell death of SZ95 sebocytes was investigated by DilC1(5)-
SYTOX Green double labelling assays following the indicated 24-hr treatments. 
Results are expressed in the percentage of the vehicle control (100%, solid line) as 
mean±SEM of four independent determinations. One additional experiment yielded 
similar results. ** and *** mark significant (P<0.01 or 0.001, respectively) differences 
compared to the vehicle control.   
CBC: (-)-cannabichromene; CBDV: (-)-cannabidivarin; CBG: (-)-cannabigerol;   
CBGV: (-)-cannabigerovarin; THCV: (-)-Δ9-tetrahydrocannabivarin.  
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Supplementary Figure S6 High concentrations of the pCBs suppressed sebaceous 
lipid synthesis 
Sebaceous lipid production of SZ95 sebocytes was assessed by Nile Red staining 
following 24-hr treatments. Results are expressed in the percentage of the vehicle 
control (100%, solid line) as mean±SEM of four independent determinations. One 
additional experiment yielded similar results. ** and *** mark significant (P<0.01 or 
0.001, respectively) differences compared to the vehicle control.   
CBC: (-)-cannabichromene; CBDV: (-)-cannabidivarin; CBG: (-)-cannabigerol;   
CBGV: (-)-cannabigerovarin; THCV: (-)-Δ9-tetrahydrocannabivarin. 
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Supplementary Figure S7 CBG and CBGV reduce AEA-induced lipogenesis of 
human sebocytes 
Sebaceous lipid production of SZ95 sebocytes was assessed by Nile Red staining 
following 48-hr treatments. Results are expressed in the percentage of the vehicle 
control (100%, solid line) as mean±SEM of 4-8 independent determinations. One 
additional experiment yielded similar results. * and *** mark significant (P<0.05 or 
0.001, respectively) differences compared to the AEA-treated group.   
AEA: anandamide; CBG: (-)-cannabigerol; CBGV: (-)-cannabigerovarin. 
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Supplementary Figure S8 THCV exerts universal lipostatic effects 
(a-b) Sebaceous lipid production of SZ95 sebocytes was monitored by Nile Red 
staining following 48-hr treatments. Results are expressed in the percentage of the 
vehicle control (100%, solid line) as mean±SEM of 4 independent determinations. 
One additional experiment yielded similar results. *** marks significant (P<0.001) 
differences as indicated.   
2-AG: 2-arachidonoylglycerol; AEA: anandamide;   
THCV: (-)-Δ9-tetrahydrocannabivarin. 
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Supplementary Figure S9 pCBs exert remarkable anti-inflammatory actions in 
human sebocytes 
(a-e) qPCR analyses of SZ95 sebocytes following the indicated 3-hr simultaneous 
treatments. Data are presented by using ΔΔCT method regarding 18S RNA-
normalized mRNA expressions of the vehicle control as 1 (solid line). Data are 
expressed as mean±SD of 2-3 determinations (a: IL-1α; b: IL-1β; c: IL-6; d: IL-8; e: 
TNF-α). One additional experiment yielded similar results. *** marks significant 
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(P<0.001) differences compared to the LPS-treated group.   
CBC: (-)-cannabichromene; CBDV: (-)-cannabidivarin; CBG: (-)-cannabigerol;  
CBGV: (-)-cannabigerovarin; pCB: phytocannabinoid;   
THCV: (-)-Δ9-tetrahydrocannabivarin. 
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